Symptoms that deserve a conversation with your doctor — and patterns that are part of the expected transition.
A 1-minute view of what this section covers. Tap any item to read the full discussion.
In the SWAN cohort, the association held after adjusting for hot flashes, snoring, and depression. 23% of women fell in the persistent high-insomnia trajectory.
Read full discussion →In a 19-year SWAN study, consistently high pre-FMP depressive symptoms predicted postmenopausal depression with OR 6.88. Proactive monitoring during the transition is evidence-supported.
Read full discussion →About half of women experience moderate-to-high palpitations during peri/early postmenopause. SWAN models found no independent association with carotid or arterial stiffness measures after accounting for BMI, BP, glucose, and sleep.
Read full discussion →Provider-initiated menopause conversations were essentially absent across African American, UK Muslim, Nigerian, and Omani women studied.
Read full discussion →Most had no prior psychiatric history. Among those who tried antidepressants, only 5 of 19 reported benefit. This is a small qualitative signal, not a prevalence estimate — but it documents a pattern where delays in appropriate care made outcomes worse.
Read full discussion →Perimenopause produces a wide range of symptoms, and many common symptoms are uncomfortable, disruptive, and often unrecognized without being, by themselves, evidence of serious disease. This section separates the patterns where the evidence calls for clinical attention from those that are broadly reassuring at the population level.
Women with a prior history of major depressive disorder had a 59% recurrence rate during midlife, compared to 28% without prior history — and 13 times more depressive symptoms during perimenopause (120). In a 19-year SWAN longitudinal study, women with consistently high depressive symptoms before their final menstrual period were the highest-risk group for postmenopausal depression (OR 6.88); the moderate-symptom group also had elevated risk (OR 2.62). The pre-FMP trajectory was a stronger predictor than concurrent factors (12).
If you have a history of depression, this is worth discussing with your doctor as you enter the perimenopausal transition — the evidence supports proactive monitoring rather than waiting for symptoms to worsen.
Mood and cognitive symptoms during perimenopause can be mistaken for other medical or mental health conditions, delaying appropriate care. Differentiating menopause-linked symptoms from pathological depression involves evaluating timing relative to the menstrual cycle and transition stage, symptom severity, personal history, and risk factors. Screening tools such as the PHQ-9, GAD-7, and menopause-specific scales can help orient the conversation, but clinical evaluation — not scales alone — makes the distinction (120, 107). See the Mood, Sleep & Cognition section for the full evidence on cognitive and mood symptoms.
Irregular bleeding during perimenopause is often physiologic — anovulation leads to insufficient progesterone and irregular shedding. But the source literature explicitly states this should not be assumed without ruling out concerning causes.
Patterns the source literature highlights for evaluation: intermenstrual or postcoital bleeding. In cited questionnaire studies, self-reported heavy menstrual bleeding was much less likely to resolve without recurrence over 24 months (9.8%, 95% CI 7.7-12.4%) compared to intermenstrual or postcoital bleeding (57%, 95% CI 52-63%). Endometrial-cancer risk factors that lower the threshold for workup include family history, HNPCC/Lynch syndrome, PCOS, tamoxifen use, and elevated waist-to-hip ratio. Anemia from heavy bleeding is a separate concern that warrants treatment on its own merits (34).
AUB visits may be an opportunity for mental health screening. In a Chinese retrospective cohort of 1,234 perimenopausal women with AUB, 33.9% had comorbid anxiety and depression — the largest of four subgroups. This is association data, not causal evidence — AUB does not cause depression. But the co-occurrence rate suggests that women presenting with heavy or irregular bleeding may benefit from depression, anxiety, and sleep screening alongside gynecological assessment (63).
A structural care gap exists in AUB evaluation. In a US national dataset of 7.9 million ED visits for non-pregnancy AUB (2014-2021), Black patients had less than half the odds of receiving ultrasound or referral compared to White patients (composite aOR 0.46). Perimenopausal-age women (46-55) had significantly lower odds of ultrasound (aOR 0.47) and referral (aOR 0.31) compared to younger women — the study authors note that providers may normalize bleeding at this age. Rural patients faced the steepest disparity (composite aOR 0.13). This is a structural process-of-care finding, not a patient-behavior gap (80).
GSM is chronic and progressive — genitourinary symptoms do not resolve without treatment. Symptoms and signs return approximately 1 month and 3 months respectively after discontinuing effective treatment (86). If you are experiencing vaginal dryness, urinary symptoms, or sexual pain that has persisted or worsened, this is worth discussing with your doctor rather than waiting — see the Genitourinary Health section.
Sexual pain is not always GSM. Dyspareunia in postmenopausal women may reflect pelvic floor hypertonus, surgical sequelae, lichen sclerosus, vestibulodynia, or pelvic organ prolapse — not only vaginal atrophy. Trauma history also affects presentation: in the cited ICSM evidence, sexual assault history was associated with 2.5 times the odds of vaginal symptoms, and emotional abuse with approximately twice the odds of urinary incontinence. A differential assessment is appropriate before attributing sexual pain to GSM alone (86).
Across multiple studied populations — African American women in the US (0% provider-initiated, 110), immigrant Muslim women in the UK (55), women in Nigeria (114), and women in Oman (118) — provider-initiated menopause conversations are essentially absent. This is a gap in how care is delivered, not something patients have missed. If your visits haven't covered menopause and you'd like them to, this is worth raising at your next appointment.
In a longitudinal study tracking symptoms every 2-6 months, "trouble sleeping because of feeling too hot" preceded conscious awareness of hot flashes by approximately 6 months (18). Unexplained new sleep disruption in midlife — especially accompanied by feeling hot — may signal the beginning of the menopausal transition before other symptoms become apparent.
In a small specialist menopause-clinic survey (n=50, 58), 48% of women had self-managed skin symptoms without consulting a doctor, often for months before connecting them to perimenopause. These symptoms are common but frequently unrecognized as menopause-related — see the Body Changes section. Dry-eye symptoms are also prevalent in midlife women (64.9% in a Thai clinic study, 82) but hormone therapy's effect on dry eye is inconsistent in the broader literature.
About half of women experience moderate-to-high palpitations during perimenopause and early postmenopause, diminishing in late postmenopause. In SWAN (n=3,276), fully adjusted models found that palpitation trajectories were not independently associated with subclinical cardiovascular disease markers (carotid intima-media thickness, pulse wave velocity) after accounting for BMI, blood pressure, glucose, and sleep (13). At the population level, this is reassuring. Chest pain, syncope, or persistent new arrhythmia fall outside the reassuring pattern described in this study and are appropriately evaluated in a clinical setting.
Cognitive changes during perimenopause — difficulty concentrating, word-finding problems, feeling mentally slower — are real and documented. For most women, these changes reflect shifts in attention rather than memory decline, and they tend to improve during postmenopause. For most women, this pattern does not by itself point to dementia. If your cognitive symptoms are severe, started suddenly, or are progressively worsening rather than fluctuating, that is a different pattern worth discussing with your doctor (53). See the Mood, Sleep & Cognition section for the full cognitive evidence.